• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For June 28, 2022

    6/28/22 7:01:08 AM ET
    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Medical/Dental Instruments
    Health Care
    Aerospace
    Industrials
    Get the next $AEMD alert in real time by email

     

    Companies Reporting Before The Bell

    • Jupai Hldgs (NYSE:JP) is projected to report earnings for its first quarter.

    • Enerpac Tool Group (NYSE:EPAC) is expected to report quarterly earnings at $0.28 per share on revenue of $155.10 million.

    • TD Synnex (NYSE:SNX) is expected to report quarterly earnings at $2.65 per share on revenue of $15.29 billion.

    • Cognyte Software (NASDAQ:CGNT) is likely to report quarterly earnings at $0.10 per share on revenue of $112.60 million.

    • Roivant Sciences (NASDAQ:ROIV) is likely to report quarterly loss at $0.32 per share on revenue of $13.35 million.

    Companies Reporting After The Bell

    • LiveOne (NASDAQ:LVO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.36 million.

    • Aethlon Medical (NASDAQ:AEMD) is expected to report quarterly loss at $0.14 per share on revenue of $720.00 thousand.

    • Progress Software (NASDAQ:PRGS) is projected to report quarterly earnings at $0.95 per share on revenue of $146.93 million.

    • AeroVironment (NASDAQ:AVAV) is projected to report quarterly earnings at $0.39 per share on revenue of $135.30 million.

    • Beyond Air (NASDAQ:XAIR) is expected to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $AVAV
    $CGNT
    $EPAC

    CompanyDatePrice TargetRatingAnalyst
    AeroVironment Inc.
    $AVAV
    3/23/2026Underperform → Mkt Perform
    Raymond James
    Roivant Sciences Ltd.
    $ROIV
    3/20/2026$35.00Outperform
    Bernstein
    AeroVironment Inc.
    $AVAV
    3/11/2026$450.00 → $400.00Buy
    Needham
    AeroVironment Inc.
    $AVAV
    3/2/2026Strong Buy → Underperform
    Raymond James
    AeroVironment Inc.
    $AVAV
    3/2/2026Strong Buy → Outperform
    Raymond James
    AeroVironment Inc.
    $AVAV
    2/18/2026$259.00Neutral
    UBS
    AeroVironment Inc.
    $AVAV
    2/17/2026$320.00Overweight
    Analyst
    Enerpac Tool Group Corp.
    $EPAC
    1/16/2026Mkt Perform
    William Blair
    More analyst ratings

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gawlick Rainer bought $74,351 worth of shares (1,710 units at $43.48), increasing direct ownership by 3% to 55,544 units (SEC Form 4)

    4 - PROGRESS SOFTWARE CORP /MA (0000876167) (Issuer)

    8/13/25 7:00:25 AM ET
    $PRGS
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Gupta Yogesh K bought $103,194 worth of shares (2,100 units at $49.14), increasing direct ownership by 0.91% to 232,396 units (SEC Form 4)

    4 - PROGRESS SOFTWARE CORP /MA (0000876167) (Issuer)

    7/24/25 7:00:24 AM ET
    $PRGS
    Computer Software: Prepackaged Software
    Technology

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AeroVironment upgraded by Raymond James

    Raymond James upgraded AeroVironment from Underperform to Mkt Perform

    3/23/26 8:22:28 AM ET
    $AVAV
    Aerospace
    Industrials

    Bernstein initiated coverage on Roivant Sciences with a new price target

    Bernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00

    3/20/26 8:36:50 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on AeroVironment with a new price target

    Needham reiterated coverage of AeroVironment with a rating of Buy and set a new price target of $400.00 from $450.00 previously

    3/11/26 8:08:12 AM ET
    $AVAV
    Aerospace
    Industrials

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TD SYNNEX Wins 2026 Google Cloud Distribution: Market Reach Partner of the Year Award

    TD SYNNEX (NYSE:SNX) announced today that it has received the 2026 Google Cloud Distribution: Market Reach Partner of the Year award. As a leading global distributor and solutions aggregator serving customers in more than 100 countries, TD SYNNEX is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers drive meaningful business outcomes through consistent support, enablement and ecosystem orchestration across the globe. "The Google Cloud Partner Awards honor the strategic innovation and measurable value our partners bring to customers," said Kevin Ichhpurani, President, Global Partner Ecosystem and Channels, Google Cloud. "We are proud to name TD SYN

    4/22/26 9:00:00 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    LiveOne (Nasdaq: LVO) Eliminates $15M+ Short-Term Liabilities, Delivering $13M+ in Cash Savings; Expands Stock Conversion Program to $15M+ at $7.50 per Share, with $8M Completed

    LOS ANGELES, April 22, 2026 (GLOBE NEWSWIRE) -- LiveOne (NASDAQ:LVO), a leading music, entertainment, and technology platform, today announced a series of strategic financial and operational milestones that significantly enhance its balance sheet and reinforce long-term growth initiatives. "This is an important step toward strengthening our balance sheet and eliminating going concern opinions," said Robert Ellin, Chairman and CEO of LiveOne. "By reducing near-term obligations and executing on our stock conversion strategy, we are enhancing financial stability and positioning the Company for long-term growth." About LiveOne Headquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an aw

    4/22/26 8:00:00 AM ET
    $LVO
    Restaurants
    Consumer Discretionary

    The Dr. Gundry Podcast Celebrates 400 Episodes, Marking a Major Milestone in Health & Wellness Media

    Dr. Steven R. Gundry Continues to Deliver Science-Backed Strategies for Better Gut Health, Longevity, and Total Wellness WorldwideLOS ANGELES, April 21, 2026 /PRNewswire/ -- The Dr. Gundry Podcast —proudly hosted by PodcastOne (NASDAQ:PODC), a leading podcast platform and a subsidiary of LiveOne (NASDAQ:LVO)—released its landmark 400th episode, underscoring its continued growth as a leading voice in the health and wellness podcast space. Created and hosted by Steven R. Gundry, M.D., world-renowned cardiothoracic surgeon, bestselling author, and founder of Gundry MD, the show has

    4/21/26 9:04:00 AM ET
    $LVO
    $PODC
    Restaurants
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Venker Eric

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/22/26 6:27:47 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Pulik Richard

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/22/26 6:26:48 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Humes Jennifer

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    4/22/26 6:26:12 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    SEC Filings

    View All

    SEC Form 424B5 filed by LiveOne Inc.

    424B5 - LiveOne, Inc. (0001491419) (Filer)

    4/23/26 4:30:11 PM ET
    $LVO
    Restaurants
    Consumer Discretionary

    LiveOne Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - LiveOne, Inc. (0001491419) (Filer)

    4/23/26 4:05:14 PM ET
    $LVO
    Restaurants
    Consumer Discretionary

    SEC Form 144 filed by Roivant Sciences Ltd.

    144 - Roivant Sciences Ltd. (0001635088) (Subject)

    4/20/26 4:17:10 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enerpac Tool Group Corp.

    SC 13G/A - ENERPAC TOOL GROUP CORP (0000006955) (Subject)

    11/14/24 1:28:29 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G filed by Enerpac Tool Group Corp.

    SC 13G - ENERPAC TOOL GROUP CORP (0000006955) (Subject)

    11/13/24 4:05:21 PM ET
    $EPAC
    Industrial Machinery/Components
    Technology

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Leadership Updates

    Live Leadership Updates

    View All

    AV Appoints Sean Woodward as Chief Financial Officer

      AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Sean T. Woodward as Executive Vice President and Chief Financial Officer, effective May 1, 2026. Woodward succeeds Kevin McDonnell, who will be stepping down from the role, as announced earlier this year. McDonnell will remain with the Company in an advisory role through July 2026 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260412005321/en/Sean Woodward is a seasoned finance leader with more than 22 years of experience in defense technology, including at A

    4/13/26 8:00:00 AM ET
    $AVAV
    Aerospace
    Industrials

    AV Appoints Dr. Robert Smith as Chief Operating Officer

    Defense Veteran to Strengthen Operational Execution as AV Scales Manufacturing and Supply Chain Capabilities AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Dr. Robert (Rob) Smith as Executive Vice President and Chief Operating Officer, effective April 13, 2026. In this role, Dr. Smith will oversee the Company's Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE) business units, as well as the Company's global operations and manufacturing footprint. His appointment reflects AV's continued focus on scaling manufacturing to meet rising customer demand, strengthening operational execution and enhancing capabi

    4/9/26 9:10:00 AM ET
    $AVAV
    Aerospace
    Industrials

    Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

    GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th

    3/26/26 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AEMD
    $AVAV
    $CGNT
    $EPAC
    Financials

    Live finance-specific insights

    View All

    LiveOne (Nasdaq: LVO) Eliminates $15M+ Short-Term Liabilities, Delivering $13M+ in Cash Savings; Expands Stock Conversion Program to $15M+ at $7.50 per Share, with $8M Completed

    LOS ANGELES, April 22, 2026 (GLOBE NEWSWIRE) -- LiveOne (NASDAQ:LVO), a leading music, entertainment, and technology platform, today announced a series of strategic financial and operational milestones that significantly enhance its balance sheet and reinforce long-term growth initiatives. "This is an important step toward strengthening our balance sheet and eliminating going concern opinions," said Robert Ellin, Chairman and CEO of LiveOne. "By reducing near-term obligations and executing on our stock conversion strategy, we are enhancing financial stability and positioning the Company for long-term growth." About LiveOne Headquartered in Los Angeles, CA, LiveOne (Nasdaq: LVO) is an aw

    4/22/26 8:00:00 AM ET
    $LVO
    Restaurants
    Consumer Discretionary

    LiveOne (Nasdaq: LVO) Partners with Team Boxing League (TBL) to Stream 60+ Live Events Across 200+ Countries through June 12, 2026, Leading into the TBL Championship

    Upcoming Schedule: Fri. April 10 — NYC Attitude vs. Las Vegas HustleSat. April 11 — Philadelphia Smoke vs. San Antonio SnipersSun. April 12 — LA Elite vs. Nashville SmashFri. April 17 — Phoenix Fury vs. Dallas EnforcersSat. April 18 — Houston Hitmen vs. Atlanta AttackSun. April 19 — Miami Assassins vs. Boston Butchers Partnership Details: Built on LiveOne's expansive 200M+ global viewer reach and 5B+ fan engagements, amplifying TBL's worldwide exposureLeverages LiveOne's proven track record in delivering large-scale live events, including successful pay-per-view productions such as Social GlovesFurther expands LiveOne's premium live sports and entertainment streaming portfolio alongside

    4/10/26 8:00:00 AM ET
    $LVO
    Restaurants
    Consumer Discretionary

    Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

    Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

    4/2/26 5:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care